Dosing, Monitoring, and Risks in the Treatment of Acute Promyelocytic Leukemia

This chapter discusses the dosing of Atra and ATO for the treatment of Acute Promyelocytic Leukemia (APL) based on the NCCN guidelines, emphasizes the importance of monitoring the patient's QTC, potassium, and magnesium levels, and outlines potential risks and treatment options for differentiation syndrome.